Anti-androgen for myoepithelial tumor: a potent therapy yet a potential misleader.

Abstract

Myoepithelial tumor is a rare form of cancer, mainly arising from the salivary glands and extremities. Due to its rarity, no formal treatment guidelines exist. Here we report a case of a male patient diagnosed with metastatic myoepithelial tumor which was successfully treated with an androgen-receptor (AR) antagonist (bicalutamide), based on the results of molecular testing. Six years after the initiation of bicalutamide, patient was diagnosed with metastatic prostate cancer. To our knowledge, this is the first case described in literature that demonstrate the effectiveness of anti-androgens in treating myoepithelial tumor. Vigilance should be maintained when screening these patients for prostate cancer as their 'true' prostate specific antigen levels might be masked by the ongoing endocrine therapy.

• Authors: Adham Hijab, Tarek Taha, Tomer Charas, Gil Bar-Sela, Polina Stein, Abed Agbarya
• Journal: Anti-cancer drugs (Anticancer Drugs) Vol. 33 Issue 1 Pg. e747-e751 (01 01 2022) ISSN: 1473-5741 [Electronic] England
• PMID: 34387605 (Publication Type: Case Reports, Journal Article)
• Copyright: Copyright © 2021 Wolters Kluwer Health, Inc. All rights reserved.

Chemical References

• Androgen Antagonists
• Anilides
• Nitriles
• Tosyl Compounds
• bicalutamide
• Prostate-Specific Antigen

Topics

• Aged
• Androgen Antagonists (therapeutic use)
• Anilides (therapeutic use)
• Humans
• Lung Neoplasms (drug therapy)
• Male
• Myoepithelioma (drug therapy)
• Neoplasm Metastasis
• Nitriles (therapeutic use)
• Prostate-Specific Antigen (drug effects)
• Prostatic Neoplasms (pathology)
• Tosyl Compounds (therapeutic use)